Ligand Pharmaceuticals Incorporated
$5.31B- Market cap
- $5.67B
- Debt
- +$374.08M
- Cash
- −$733.52M
Capital structure 94% equity / 6% debt · EV / Revenue 19.81x · EV / EBITDA 33.13x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: LGND stock price at premium vs MTCH $284.43 current versus $106.81 implied using P/E multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at MTCH's multiple
Implied fair value · at LGND's multiple
Snapshot Sep 8, 2026, 1:59 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Pricing power
Operating leverage
Multiple premium
Premium justified
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: LGND FY 2025 (ended Dec 31, 2025) · MTCH FY 2025 (ended Dec 31, 2025).
Trendline
Five fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 94% equity / 6% debt · EV / Revenue 19.81x · EV / EBITDA 33.13x
Capital structure 71% equity / 29% debt · EV / Revenue 3.57x · EV / EBITDA 13.30x
MTCH carries the larger enterprise value at $12.46B against $5.31B; MTCH trades on the lower EV / Revenue multiple (3.57x vs 19.81x); MTCH on the lower EV / EBITDA (13.30x vs 33.13x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
LIGAND PHARMACEUTICALS INCORPORATED · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Match Group, Inc. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
0.37x
-15.67x
Net debt / EBITDA
Leverage against operating earnings
-2.24x
3.14x
Cash and equivalents
Liquid reserves on the balance sheet
$733.52M
$1.03B
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Royalty Pharma plc
LGND vs RPRX
Sarepta Therapeutics, Inc.
LGND vs SRPT
INCYTE CORP
LGND vs INCY
EXELIXIS, INC.
LGND vs EXEL
Meta Platforms, Inc.
LGND vs META
Snap Inc
LGND vs SNAP
PINTEREST, INC.
LGND vs PINS
VERISIGN INC/CA
LGND vs VRSN
Apple Inc.
LGND vs AAPL
NVIDIA CORP
LGND vs NVDA
$374.08M
$3.97B
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.